Suppr超能文献

长期阿仑膦酸盐治疗对绝经后骨质疏松症骨材料特性的影响。

Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties.

作者信息

Hassler N, Gamsjaeger S, Hofstetter B, Brozek W, Klaushofer K, Paschalis E P

机构信息

Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma CentreMeidling, 1st Medical Department, Hanusch Hospital, Heinrich Collin Str. 30, A-1140, Vienna, Austria.

出版信息

Osteoporos Int. 2015 Jan;26(1):339-52. doi: 10.1007/s00198-014-2929-5. Epub 2014 Oct 15.

Abstract

UNLABELLED

Raman microspectroscopic analysis of iliac crest from patients that were treated with alendronate (ALN) for 10 years revealed minimal, transient alterations in bone material properties confined to actively forming bone surfaces compared to patients that were on ALN for 5 years. These changes were not encountered in the bulk tissue.

INTRODUCTION

Alendronate (ALN) and other bisphosphonates (BPs) are the most widely prescribed therapy for postmenopausal osteoporosis. Despite their overall excellent safety record and efficacy in reducing fractures, questions have been raised regarding potential detrimental effects that may be related to prolonged bone turnover reduction, although no definite cause-effect relationship has been established to date. The purpose of the present study was to evaluate bone material properties in patients that were receiving ALN for 5 or 10 years.

METHODS

Raman microspectroscopic analysis was used to analyze iliac crest biopsies from postmenopausal women with osteoporosis who had been treated with ALN for 5 years and were then re-randomized to placebo (PBO, N = 14), 5 mg/day ALN (N = 10), or 10 mg/day ALN (N = 6) for another 5 years. The parameters monitored and expressed as a function of tissue age were (i) the mineral/matrix ratio (MM), (ii) the relative proteoglycan content (PG), (iii) the relative lipid content (LPD), (iv) the mineral maturity/crystallinity (MMC), and (v) the relative pyridinoline content (PYD).

RESULTS

The obtained data indicate that 10-year ALN use results in minimal, transient bone tissue composition changes compared to use for 5 years, confined to actively forming trabecular surfaces, implying potential differences in bone matrix maturation that nevertheless did not result in differences of these values in bulk tissue.

CONCLUSIONS

The data suggest that prolonged reduction in bone turnover during 10 years of therapy with ALN by itself is unlikely to be associated with adverse effects on bone material properties.

摘要

未标注

对接受阿仑膦酸盐(ALN)治疗10年的患者的髂嵴进行拉曼光谱分析发现,与接受ALN治疗5年的患者相比,骨材料特性的变化最小且短暂,局限于活跃形成的骨表面。在大块组织中未观察到这些变化。

引言

阿仑膦酸盐(ALN)和其他双膦酸盐(BPs)是绝经后骨质疏松症最常用的治疗药物。尽管它们总体安全性良好且在降低骨折风险方面疗效显著,但关于长期减少骨转换可能产生的潜在有害影响的问题已经出现,尽管迄今为止尚未确立明确的因果关系。本研究的目的是评估接受ALN治疗5年或10年的患者的骨材料特性。

方法

采用拉曼光谱分析对患有骨质疏松症的绝经后女性的髂嵴活检样本进行分析,这些女性已接受ALN治疗5年,然后重新随机分为安慰剂组(PBO,N = 14)、5毫克/天ALN组(N = 10)或10毫克/天ALN组(N = 6),再治疗5年。监测并作为组织年龄函数表示的参数有:(i)矿物质/基质比(MM),(ii)相对蛋白聚糖含量(PG),(iii)相对脂质含量(LPD),(iv)矿物质成熟度/结晶度(MMC),以及(v)相对吡啶啉含量(PYD)。

结果

获得的数据表明,与使用5年相比,使用ALN 10年导致的骨组织成分变化最小且短暂,局限于活跃形成的小梁表面,这意味着骨基质成熟存在潜在差异,但并未导致大块组织中这些值出现差异。

结论

数据表明,在10年的ALN治疗期间,骨转换长期减少本身不太可能对骨材料特性产生不利影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验